uniQure N.V. Other Accounts Payable and Accrued Liabilities
uniQure N.V. (QURE) had Other Accounts Payable and Accrued Liabilities of $3.56 million as of 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements › Notes › Payables and Accruals
us-gaap:OtherAccountsPayableAndAccruedLiabilities · last filed 2026-05-05
- 2026-03-31: Other Accounts Payable and Accrued Liabilities $3.56M.
- 2025-12-31: Other Accounts Payable and Accrued Liabilities $5.52M.
- 2025-09-30: Other Accounts Payable and Accrued Liabilities $3.58M.
- 2025-06-30: Other Accounts Payable and Accrued Liabilities $5.25M.
| Period end | Other Accounts Payable and Accrued Liabilities |
|---|---|
| 2026-03-31 | $3.56M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $5.52M 10-Q · filed 2026-05-05 |
| 2025-09-30 | $3.58M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $5.25M 10-Q · filed 2025-07-29 |
| 2025-03-31 | $1.58M 10-Q · filed 2025-05-09 |
| 2024-12-31 | $4.95M 10-K · filed 2026-03-02 |
| 2024-09-30 | $2.08M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $1.90M 10-Q · filed 2024-08-01 |
| 2024-03-31 | $1.21M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $1.44M 10-K · filed 2025-02-27 |
| 2023-09-30 | $495.00K 10-Q · filed 2023-11-07 |
| 2023-06-30 | $771.00K 10-Q · filed 2023-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |